Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review.
Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults...
| Publicado en: | International Wound Journal Vol. 16; no. 2; pp. 511 - 522 |
|---|---|
| Autores principales: | , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Apr2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135425381&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135425381 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17424801 1725 jtl: International Wound Journal issn: 17424801 maglogo: Y pubinfo: dt: Apr2019 vid: 16 iid: 2 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 135425381 135425381 135425381 10.1111/iwj.13067 135425381 ppf: 511 ppct: 11 formats: tig: atl: Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. aug: au: Ben Abdallah, Hakim Fogh, Karsten Bech, Rikke affil: Institute of Clinical Medicine, Aarhus Faculty of Health Sciences, Aarhus University, Aarhus Denmark sug: subj: Pyoderma Gangrenosum Drug Therapy Tumor Necrosis Factor Antagonists and Inhibitors Clinical Effectiveness Human Systematic Review PubMed Embase Pyoderma Gangrenosum Diagnosis Adolescence Confidence Intervals Infliximab Therapeutic Use Adalimumab Therapeutic Use Etanercept Therapeutic Use Treatment Outcomes Adolescent: 13-18 years ab: Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNFα inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNFα inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%‐90%) response rate and a 67% (95% CI: 62%‐72%) complete response rate to TNFα inhibitors. No statistically significant differences in the response rates (P = 0.6159) or complete response rates (P = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNFα inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNFα inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept. pubtype: Academic Journal doctype: research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|